Primary Biliary Cirrhosis Treatment Market By Drug Type; By Surgery; By Diagnosis Test & By Geography - Forecast 2016-2021

  • ID: 3974098
  • Report
  • 153 pages
  • IndustryARC
1 of 3
Primary biliary cirrhosis, also known as primary biliary cholangitis (PBC), is an autoimmune disease of the liver which is relatively rare as compared to other gastro diseases. The advanced stage of PBC is considered as cirrhosis. Identification, diagnosis and treatment differ based on the severity of PBC and patients’ condition. Several diagnosis tests are recommended including blood tests, imaging tests and liver biopsy which further encompass several test methods. The treatment includes medication approach as well as surgical approach. Medical approach includes employment of approved drugs individually or in combination including Ursodeoxycholic Acid, Corticosteroids and Methotrexate which are marketed under different brand names. Obeticholic Acid, new drug is under clinical trials and is expected to be launched in the near future.

The growth of this market is primarily attributed to increasing availability of treatment services and drugs. In addition, to drugs, liver transplantation is performed which completely prevents PBC. Establishment of diagnosis and treatment standards in the recent years boosts the overall service experience as well as treatment outcomes which propels the market growth. Driven by the aforementioned factors, this market is set to reach $XX billion by 2021, growing at a CAGR of XX% during 2016-2021.

North America held a major share of XX% in the PBC drugs market, followed by Europe and APAC. Commercialization of new drugs and expanding specialized services for liver in India and China is set to boost the market revenue in APAC region.

The key players in the PBC Drugs market include:

Sanofi S.A.

Intercept Pharmaceuticals, Inc.

Mylan N.V.

Mankind Pharmaceuticals Pvt. Ltd.

The estimates and forecasts have been derived based on various inputs from primary and secondary sources. Secondary sources such as articles, whitepapers, journals and other has helped to deliver an extensive analysis in this report. Insights related to various regulatory frameworks and clinical studies have been collected from publications by health regulatory agencies. To enhance the accuracy of the estimates, the data has been validated by conducting interviews with industry experts. This report on the PBC treatment market identifies many such insights, new product developments, besides providing a detailed analysis of the key drug companies, treatment service providers and growth potential of the market.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Primary Biliary Cirrhosis Treatment Market Overview
1.1. Introduction
1.2. Classification

2. Executive Summary

3. PBC Treatment Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. Patent Analysis
3.2.3. Financials of Key Players

4. PBC Treatment Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Suppliers Power
4.4.2. Bargaining Power of Buyer
4.4.3. Threat from New Entrants
4.4.4. Threats from Substitutes
4.4.5. Degree of Competition

5. PBC Treatment Market – Strategic Analysis
5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis

6. PBC Drugs Market– By Type
6.1. Ursodeoxycholic Acid
6.2. Obeticholic Acid
6.3. Corticosteroids
6.4. Methotrexate
6.5. Others

7. PBC Surgery Market
7.1. Introduction
7.2. Liver Transplant Services

8. PBC Diagnosis Tests Market- By Type
8.1. Blood Tests
8.1.1. AMA Test
8.1.2. ALT Test
8.1.3. AST Test
8.1.4. ALP Test
8.1.5. Others
8.2. Imaging Tests
8.2.1. Ultrasound
8.2.2. CT Scan
8.2.3. MRI
8.2.4. Others
8.3. Liver Biopsy

9. PBC Treatment Market-Geographic Analysis
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. U.K.
9.3.2. Germany
9.3.3. France
9.3.4. Russia
9.3.5. Rest of Europe
9.4. APAC
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of APAC
9.5. RoW
9.5.1. South America
9.5.2. Middle East
9.5.3. Africa

10. Market Entropy

11. Company Profiles (Overview, Financials, Developments and Product Portfolio)
11.1. Mankind Pharmaceuticals Pvt. Ltd.
11.2. Solvay Pharma India Pvt Ltd
11.3. Zydus Pharmaceuticals
11.4. Mylan N.V.
11.5. Hexal AG
11.6. Sanofi S.A.
11.7. Sigma Pharmaceuticals Ltd
11.8. Intercept Pharmaceuticals, Inc.
11.9. Teva Pharmaceuticals Industries Ltd
11.10. FF Pharma

12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Bibliography
12.5. Compilation of Expert Insights
12.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: